Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?
Rafael CaparicaClaudia De AngelisÂngelo FêdeGustavo WerutskyEvandro de AzambujaPublished in: Expert review of anticancer therapy (2020)
Retrospective series and early-phase clinical trials have shown promising signs of activity and a favorable toxicity profile with this regimen, which warrants further investigation as a treatment option for luminal breast cancer patients.